In situ Hybridization Market is projected to reach USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 12.6% during the forecast period. One of the key driving factors of the in situ hybridization market is the increasing awareness of companion diagnostics and the growing incidence of cancer and genetic disorders. Moreover, the growth of the ISH market is largely driven by a rise in government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of innovative technologies and methodologies in the fields of tissue and in vitro diagnostics.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829

Browse in-depth TOC on "In situ Hybridization Market”

235 – Tables

31 – Figures

201 – Pages

Key Market Players

The in situ hybridization market is consolidated in nature with prominent players in the in situ hybridization market including Abbott (US), Abcam (UK), Abnova Corporation (Taiwan), Agilent Technologies, Inc. (US), Bio SB Inc. (US), Biocare Medical, LLC (US), BioCat GmbH (Germany), BioGenex Laboratories (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), BioView (Israel), Creative Bioarray (US), Danaher (US), Enzo Biochem (US), F. Hoffmann-La Roche AG (Switzerland), GeneMed Biotechnologies Inc. (US), Merck KGaA (Germany), NeoGenomics Laboratories (US), OpGen (US), Oxford Gene Technology (UK), PerkinElmer Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific (US), and ZytoVision GmbH (Germany).

Abbott (US)

Abbott (US) caters to the in situ hybridization market via its diagnosis business segment. Molecular division products such as kits and reagents, accessories, instruments, and software are a part of the company’s product portfolio. Abbott is recognized for its robust presence across different geographies including, the US, Germany, India, South Korea, and North America. The company’s key focus lies in product development and commercialization of in situ hybridization to sustain market competition.

F.Hoffmann-La Roche AG

Hoffmann-La Roche AG has a strong market presence in North America, and Europe region. The company offers in situ hybridization products for the diagnosis of patients suffering from cancer. F. Hoffmann-La Roche AG has adopted organic growth strategies and has a prime focus on the development and commercialization of in situ hybridization candidates in the pipeline. Therapeutic applications such as neurological disorders and pulmonary ailments are two of the key areas of investment for the company through which it is expected to broaden its hold on the in situ hybridization market. The revenue in the company’s Life Sciences segment increased by 8% in the last year due to the increasing demand in developed and emerging markets for life science products.

Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=212028829

The Asia Pacific region is the fastest-growing region of the in situ hybridization market in 2021.

The Asia Pacific region is estimated to grow at the highest CAGR in the in situ hybridization market during the forecast period. China and India are the key revenue contributors to the Asia Pacific in situ hybridization market. Favorable government support for product approvals and the presence of major players in these countries are anticipated to drive regional market growth.

Key drivers of the in situ hybridization market include rising incidence of genetic disorders and cancer, and growing awareness of companion diagnostics. However, a shortage of skilled professionals poses a significant challenge to the growth of this market.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=212028829

Browse Adjacent Market: 3D Bioprinting Market Research Reports Consulting

Related Reports:

Skin Health Foods Market / Dermatology Functional Foods Market by Indication (Skin Conditions, Anti-Aging, Anti-Allergy), Region (North America, Europe, Asia Pacific, Rest of the World), Regulatory Landscape, Pricing Analysis, COVID-19 Impact - Global Forecast to 2026

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/clinical-trials-market.asp

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/gene-therapy.asp